sitagliptin
Selected indexed studies
- Efficacy and Safety of Sitagliptin in the Treatment of COVID-19. (J Pharm Pract, 2023) [PMID:35581701]
- Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study. (Sci Rep, 2023) [PMID:36599895]
- Sitagliptin: A Review in Type 2 Diabetes. (Drugs, 2017) [PMID:28078647]
_Worker-drafted node — pending editorial review._
Connections
sitagliptin is a side effect of
Sources
- Efficacy and Safety of Sitagliptin in the Treatment of COVID-19. (2023) pubmed
- Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study. (2023) pubmed
- Sitagliptin: A Review in Type 2 Diabetes. (2017) pubmed
- Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy? (2022) pubmed
- Sitagliptin to Prevent Acute Graft-versus-Host Disease. (2021) pubmed
- Sitagliptin as an Add-on Therapy to Other Glucose-lowering Agents in Patients with Type 2 Diabetes Mellitus: A Narrative Review. (2025) pubmed
- Sitagliptin. (2007) pubmed
- Sitagliptin eye drops prevent the impairment of retinal neurovascular unit in the new Trpv2(+/-) rat model. (2024) pubmed
- Sitagliptin for Type 2 diabetes: a 2015 update. (2015) pubmed
- Comparison of the effects of empagliflozin and sitagliptin, as an add-on to metformin, on cardio-metabolic and glycemic parameters of patients with type 2 diabetes mellitus: a randomized, double-blind clinical trial. (2025) pubmed